218 related articles for article (PubMed ID: 35671079)
21. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
22. High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study.
Parbie PK; Abana CZ; Kushitor D; Asigbee TW; Ntim NAA; Addo-Tetebo G; Ansong MRD; Ofori SB; Mizutani T; Runtuwene LR; Nishizawa M; Ishikawa K; Kiyono H; Ampofo WK; Matano T; Bonney EY; Kikuchi T
Front Microbiol; 2022; 13():973771. PubMed ID: 36090108
[TBL] [Abstract][Full Text] [Related]
23. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan.
Ruzicka DJ; Kamakura M; Kuroishi N; Oshima N; Yamatani M; Yi J; Crawford B; Tsukada K; Oka S
PLoS One; 2022; 17(6):e0269779. PubMed ID: 35700215
[TBL] [Abstract][Full Text] [Related]
25. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
26. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
[TBL] [Abstract][Full Text] [Related]
27. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
28. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.
Neesgaard B; Mocroft A; Zangerle R; Wit F; Lampe F; Günthard HF; Necsoi C; Law M; Mussini C; Castagna A; Monforte AD; Pradier C; Chkhartisvilli N; Reyes-Uruena J; Vehreschild JJ; Wasmuth JC; Sönnerborg A; Stephan C; Greenberg L; Llibre JM; Volny-Anne A; Peters L; Pelchen-Matthews A; Vannappagari V; Gallant J; Rieger A; Youle M; Braun D; De Wit S; Petoumenos K; Borghi V; Spagnuolo V; Tsertsvadze T; Lundgren J; Ryom L;
PLoS One; 2020; 15(12):e0243625. PubMed ID: 33382756
[TBL] [Abstract][Full Text] [Related]
29. Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor-Based Combination Antiretroviral Therapy.
Dijkstra S; Hofstra LM; Mudrikova T; Wensing AMJ; Oomen PGA; Hoepelman AIM; van Welzen BJ
J Acquir Immune Defic Syndr; 2022 Apr; 89(5):575-582. PubMed ID: 34966148
[TBL] [Abstract][Full Text] [Related]
30. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
31. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Volny Anne A; Öllinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K;
HIV Med; 2022 Sep; 23(8):895-910. PubMed ID: 35233903
[TBL] [Abstract][Full Text] [Related]
32. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
33. Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
Ndembi N; Murtala-Ibrahim F; Tola M; Jumare J; Aliyu A; Alabi P; Mensah C; Abimiku A; Quiñones-Mateu ME; Crowell TA; Rhee SY; Shafer RW; Gupta R; Blattner W; Charurat ME; Dakum P
AIDS Res Ther; 2020 Nov; 17(1):64. PubMed ID: 33143751
[TBL] [Abstract][Full Text] [Related]
34. Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV.
Guaraldi G; Milic J; Bacchi E; Carli F; Menozzi M; Franconi I; Raimondi A; Ciusa G; Masi V; Belli M; Guaraldi S; Aprile E; Mancini M; Mussini C; Lake JE; Erlandson KM
HIV Res Clin Pract; 2022 Nov; 24(1):1-6. PubMed ID: 36883678
[No Abstract] [Full Text] [Related]
35. Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
Adams JL; Murray M; Patel N; Sawkin MT; Boardman RC; Pham C; Kaur H; Patel D; Yager JL; Pontiggia L; Baxter J
HIV Med; 2021 Jan; 22(1):28-36. PubMed ID: 32964664
[TBL] [Abstract][Full Text] [Related]
36. Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.
Richter E; Bornemann L; Korencak M; Alter G; Schuster M; Esser S; Boesecke C; Rockstroh J; Gunzer M; Streeck H
J Virol; 2022 Mar; 96(5):e0173021. PubMed ID: 35019724
[TBL] [Abstract][Full Text] [Related]
37. Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV.
Climaco-Arvizu S; Flores-López V; González-Torres C; Gaytán-Cervantes FJ; Hernández-García MC; Zárate-Segura PB; Chávez-Torres M; Tesoro-Cruz E; Pinto-Cardoso SM; Bekker-Méndez VC
BMC Infect Dis; 2022 May; 22(1):447. PubMed ID: 35538426
[TBL] [Abstract][Full Text] [Related]
38. Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors.
O'Halloran JA; Cooley SA; Strain JF; Boerwinkle A; Paul R; Presti RM; Ances BM
AIDS; 2019 Jul; 33(9):1477-1483. PubMed ID: 31008801
[TBL] [Abstract][Full Text] [Related]
39. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.
Pugliese P; Joly V; Valantin MA; Cotte L; Huleux T; Allavena C; Reynes J; Poizot-Martin I; Bani-Sadr F; Cuzin L;
Med Mal Infect; 2019 Jun; 49(4):264-269. PubMed ID: 30409541
[TBL] [Abstract][Full Text] [Related]
40. Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study.
Harding BN; Whitney BM; Nance RM; Crane HM; Burkholder G; Moore RD; Mathews WC; Eron JJ; Hunt PW; Volberding P; Rodriguez B; Mayer K; Saag MS; Kitahata MM; Heckbert SR; Delaney JAC
BMJ Open; 2020 Mar; 10(3):e031487. PubMed ID: 32198297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]